A focused strategy to bring meaningful therapies to patients who need them most
ADC Therapeutics is advancing a targeted portfolio utilizing our highly potent pyrrolobenzodiazepine (“PBD”) technology and a differentiated exatecan-based payload with a novel hydrophilic linker.
We are seeking to continue expanding ZYNLONTA into earlier lines of DLBCL and indolent lymphomas, including marginal zone lymphoma (MZL) and follicular lymphoma (FL”), as a single agent and in combination through our LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial as well as through investigator-initiated trials (IITs) at leading institutions.
In addition, IND-enabling activities are underway for the Company’s exatecan-based, prostate-specific membrane antigen (PSMA)-targeting ADC (ADCT-241), which has been selected for advancement.
By leveraging decade-long expertise in the ADC field with multiple INDs and a proven track record of success, ADC Therapeutics is focused on driving innovation in ADC development to bring meaningful therapies to patients in need.
| Preclinical | Phase 1a | Phase 1b | Phase 2 | Phase 3/ Confirmatory | |||
|---|---|---|---|---|---|---|---|
| ZYNLONTA (Loncastuximab Tesirine-lpyl) | |||||||
LOTIS-2 in 3L+ r/r DLBCL |
Description | ||||||
LOTIS-5 in r/r DLBCL |
Description | ||||||
LOTIS-7 in r/r B-NHL |
Description | ||||||
| ADCT-241 | |||||||
Prostate Cancer |
|||||||
| ZYNLONTA (Loncastuximab Tesirine-lpyl) | ||
| LOTIS-2 in 3L+ r/r DLBCL | ||
A Phase 2 open-label single-arm study to evaluate the efficacy and safety of loncastuximab tesirine-lpyl in patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL). ZYNLONTA® Targeting CD19 | ||
| Phase 3/ Confirmatory | ||
| LOTIS-5 in r/r DLBCL | ||
A Phase 3 randomized Study of loncastuximab tesirine-lpyl combined with rituximab versus immunochemotherapy in patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL). ZYNLONTA® Targeting CD19 | ||
| Phase 3/ Confirmatory | ||
| LOTIS-7 in r/r B-NHL | ||
A Phase 1b, open-label study to evaluate the safety and efficacy of loncastuximab tesirine-lpyl in combination in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory B-cell lineage non-Hodgkin Lymphoma (B-NHL). ZYNLONTA® Targeting CD19 | ||
| Phase 1b | ||
| ADCT-241 | ||
| Prostate Cancer | ||
| Preclinical | ||
For physicians, visit adctmedical.com to find more information on our clinical trials. For patients, visit our clinical trial page to find more information.